

Special Issue

The Development of HIV Vaccines: Advances and Challenges

Message from the Guest Editor

This Special Issue aims to showcase research and emerging challenges in developing HIV vaccines. We invite original research articles, reviews, and perspectives that explore novel immunogens, innovative adjuvants, and advancements in vaccine delivery platforms. Submissions that focus on immune correlates of protection, strategies to elicit broadly neutralizing antibodies, and lessons learned from past vaccine trials are highly encouraged. We are particularly interested in studies that address advanced immunological concepts, including trained immunity, epigenetic reprogramming of innate responses, and the role of heterologous immunity in vaccine efficacy. Manuscripts discussing novel vaccine strategies, such as mRNA platforms, are encouraged, as are contributions that examine immune-metabolic regulation in vaccine-induced responses.

Guest Editor

Prof. Dr. Michael Bukrinsky

Department of Microbiology, Immunology & Tropical Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC 20037, USA

Deadline for manuscript submissions

31 December 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/234948

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).